BiotechTube
Camallergy

Camallergy

Cambridge, United Kingdom· Est.
camallergy.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Camallergy is a UK-based, private biotech developing patient-centric oral immunotherapies for food allergies, with an initial priority on peanut allergy. The company's programs are built upon over a decade of clinical research and real-world treatment experience at the Cambridge Peanut Allergy Clinic, where its foundational protocol has been used to treat over 200 children. Camallergy is integrating a novel dosing device into its treatment regimens to enhance precision and usability as it advances its pipeline into formal clinical trials.

Allergy & ImmunologyGastroenterology

Technology Platform

Oral immunotherapy (OIT) protocols combined with the OnDosis Dosage Manager, a precision medical device for controlled allergen powder dosing.

Opportunities

The global food allergy treatment market is large and underserved, with high demand for safer and more convenient therapies beyond the first-generation approved product.
Camallergy's clinically-validated protocol and integrated dosing device position it to potentially offer a differentiated product with a better safety and usability profile.
Expansion into other major food allergens (e.g., milk, egg, tree nuts) represents a significant long-term pipeline opportunity.

Risk Factors

The company faces clinical trial risk, as its protocol must succeed in formal regulatory studies despite prior real-world use.
It operates in a competitive and evolving regulatory landscape for allergy therapies.
As a private, pre-revenue company, it carries financing risk and depends on raising capital to advance through costly clinical development.

Competitive Landscape

Camallergy competes in the food allergy immunotherapy space, notably against Aimmune Therapeutics (now part of Nestlé Health Science), which markets the FDA/EMA-approved Palforzia for peanut allergy. Other competitors include DBV Technologies (Viaskin patch) and several biotechs developing biologics (e.g., monoclonal antibodies) and modified allergen therapies. Camallergy aims to differentiate through its precision-dosing device and a treatment regimen honed in a real-world clinical service.

More companies in Small Molecule Drugs →More companies in United Kingdom →